1. 1. (2001) FDA Oncology Tools Approval Summary for imatinib mesylate for Accel. Approv., U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Available at: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm110502.htm (last accessed 15 September 2009).
2. 2. (2005) FDA Oncology Tools Approval Summary for sorafenib for the treatment of patients with advanced renal cell carcinoma. U.S. Food and Drug Administration Center for Drug Evaluation and Research. Available at: http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm129234.htm (last accessed 15 September 2009).
3. 3. (2007) FDA Oncology Tools Approval Summary for sunitinib for the treatment of gastrointestinal stromal tumor after disease progression on or intolerance to imatinib mesylate; for the treatment of advanced renal cell carcinoma. U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Available at: http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm129255.htm (last accessed 15 September 2009).
4. The human HOX gene family;Acampora;Nucleic Acids Res,1989
5. Long term outcomes following surgical resection of myxopapillary ependymomas;Bagley;Neurosurg Rev,2009